Purpose of Glycopyrrolate Before ECT
The correct answer is
3. To dry secretions and prevent vagal slowing of the heart.
Glycopyrrolate is an
anticholinergic agent that is routinely administered before electroconvulsive therapy. Its clinical role in this setting is twofold and directly addresses two predictable physiological responses to the procedure.
First, the electrical stimulus delivered during ECT triggers an immediate, brief surge of parasympathetic outflow through the vagus nerve. This can produce
transient bradycardia or even a few seconds of
asystole at the exact moment the current is applied. Because glycopyrrolate blocks muscarinic acetylcholine receptors, it blunts this vagal response and helps maintain an adequate heart rate during stimulus delivery.
The anticholinergic effect is what prevents the brief vagal slowing of the heart that occurs at the moment of the electrical stimulus.
Second, glycopyrrolate reduces
oral and airway secretions. During the brief period of anesthesia and the induced seizure, the patient cannot protect the airway effectively. Excess saliva or respiratory secretions increase the risk of
aspiration and can complicate airway management. By drying these secretions, glycopyrrolate lowers that risk.
Watch out! Glycopyrrolate does
not lower the seizure threshold, relax skeletal muscles, or blunt the hypertensive response. Those effects are achieved by other agents given as part of the ECT anesthetic regimen.
| Drug or Agent | Primary Purpose in ECT |
|---|
| Glycopyrrolate (anticholinergic) | Dries secretions and prevents vagal bradycardia/asystole |
| Succinylcholine (muscle relaxant) | Relaxes skeletal muscles to prevent fractures and soft tissue injury during the seizure |
| Methohexital or propofol (anesthetic) | Produces brief unconsciousness so the patient does not experience the seizure |
| Beta-blocker or other antihypertensive (e.g., labetalol, esmolol) | Blunts the sympathetic surge and rise in blood pressure during the seizure |
In this patient, the order for glycopyrrolate before the anesthetic is consistent with standard ECT practice. She has controlled hypertension and no cardiac, neurologic, or pulmonary disease, so the anticholinergic is used primarily for its routine protective effects on heart rate and secretions rather than for any specific comorbidity.
Muscle relaxation, anesthesia, and blood pressure control are provided by separate drugs, not by glycopyrrolate.
Key point! When a question asks about a pre-ECT anticholinergic, the expected answer almost always involves two linked actions: reducing secretions and preventing vagal-induced bradycardia. The other options describe the roles of entirely different medication classes.